Spot on, been saying this for a year now..

Quote:

---

Regeneron/Lily MABs - I told this page’s followers back in November these drugs would fail due to mutations in my talk about why leronlimab was better than bamlanivimab. And, guess what? States are now not using those drugs because the mutations rendered them useless. This will be another pretty much failed EUA. While these drugs had initial promise, much like with the vaccines, EUA without logistics made them hard to obtain. This would compounded by the need for an infusion in an overwhelmed healthcare system (which was another colossal US healthcare failure).

Read More: https://investorshangout.com/post/newpost/605...z6ryCfO3oh

---

I'd be remiss not to highlight this:

Quote:

---

Big Pharma, whose drugs have I'd failures in really sick COVID patients (sans Roche’s tocilizumab),

---

Tocilizumab is effectively a failure as well. Meaning it actually failed several trials and did as much or more harm than good. It shouldn't even be used for arthritis, but we all know how the FDA rolls.